Drug Search Results
More Filters [+]

DTX-024

Alternative Names: DTX-024, DTX024, DTX 024
Latest Update: 2023-04-29
Latest Update Note: Clinical Trial Update

Product Description

Aquavit Holdings has submitted to FDA an IND for its DTX-024, for the treatment of palmar hyperhidrosis using its patented microchannel technology™. DTX-024 is a highly purified and clinically tested injectable neuromodulator derived from neurotoxins produced by Clostridium botulinum. (Sourced from: https://www.aquavitpharma.com/post/aquavit-files-ind-for-a-new-botulinum-toxin-with-microchannel-technology-for-palmar-hyperhidrosis)

Mechanisms of Action: Unknown

Novel Mechanism: No

Modality: N/A

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Aquavit
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for DTX-024

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 0: Hyperhidrosis

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events